clinical trial · NCT06831812
Phase I Clinical Study of AV-1959R: Abeta-targeting Anti-Alzheimer's Vaccine
Nuravax, Inc.·phase1·completed·n = 16
Alzheimer DiseaseAlzheimer Disease (AD)Alzheimers Disease PreventionAV-1959R (Abeta vaccine)
brief summary
This Phase 1 clinical trial evaluates the safety, tolerability, and immune response of the adjuvanted AV-1959R vaccine in healthy adults aged 40-60. Participants will receive three intramuscular injections of either adjuvanted AV-1959R (100 µg or 300 µg) or adjuvanted placebo at Weeks 0, 4, and 14, followed by an 8-week follow-up. Researchers will monitor for side effects and measure anti-Aβ antibody levels to assess immune response. This study will help determine if AV-1959R is safe and effective in generating a targeted immune response.
started
Jun 12, 2024
primary completion
Dec 1, 2025
completion
Dec 1, 2025
last updated
Feb 24, 2026
official title
A Phase I, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Safety, Tolerability and Immunogenicity of AV-1959R in Healthy Participants
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol